NZ757956A - Il4/il13 receptor molecule for veterinary use - Google Patents
Il4/il13 receptor molecule for veterinary useInfo
- Publication number
- NZ757956A NZ757956A NZ757956A NZ75795618A NZ757956A NZ 757956 A NZ757956 A NZ 757956A NZ 757956 A NZ757956 A NZ 757956A NZ 75795618 A NZ75795618 A NZ 75795618A NZ 757956 A NZ757956 A NZ 757956A
- Authority
- NZ
- New Zealand
- Prior art keywords
- receptor molecule
- veterinary use
- contiguous polypeptides
- il13r
- il4r
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/7455—Thrombomodulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5406—IL-4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5437—IL-13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488509P | 2017-04-21 | 2017-04-21 | |
| PCT/US2018/028507 WO2018195388A1 (en) | 2017-04-21 | 2018-04-20 | Il4/il13 receptor molecule for veterinary use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ757956A true NZ757956A (en) | 2026-02-27 |
Family
ID=63856393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ757956A NZ757956A (en) | 2017-04-21 | 2018-04-20 | Il4/il13 receptor molecule for veterinary use |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11970526B2 (https=) |
| EP (1) | EP3612555A4 (https=) |
| JP (2) | JP7657548B2 (https=) |
| KR (2) | KR20250057131A (https=) |
| CN (1) | CN110770250B (https=) |
| AU (2) | AU2018254542B2 (https=) |
| BR (1) | BR112019021812A2 (https=) |
| CA (1) | CA3059731A1 (https=) |
| MX (1) | MX2019012570A (https=) |
| NZ (1) | NZ757956A (https=) |
| WO (1) | WO2018195388A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6871948B2 (ja) | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| JP7657548B2 (ja) | 2017-04-21 | 2025-04-07 | エランコ・ユーエス・インコーポレイテッド | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
| US12297272B2 (en) * | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| EP3870601A4 (en) * | 2018-10-25 | 2022-07-13 | Kindred Biosciences, Inc. | IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| EP4139344A4 (en) * | 2020-04-22 | 2024-10-16 | Elanco US Inc. | Il4/il13 receptor molecules for veterinary use |
| WO2021249555A1 (en) * | 2020-06-12 | 2021-12-16 | Beijing Vdjbio Co., Ltd. | Fusion polypeptide |
| JP2024532158A (ja) | 2021-08-20 | 2024-09-05 | インターベット インターナショナル ベー． フェー． | アトピー性皮膚炎を治療するためのホモ二量体融合タンパク質 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US6428788B1 (en) | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
| US7078494B1 (en) | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6743604B1 (en) | 1996-12-13 | 2004-06-01 | Smithkline Beecham Corporation | Substances and their uses |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US7083949B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| MXPA01006006A (es) | 1998-12-14 | 2004-08-12 | Genetics Inst | Cadena receptora de citocina. |
| US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| US6703360B2 (en) * | 2000-04-07 | 2004-03-09 | Heska Corporation | Compositions and methods related to canine IgG and canine IL-13 receptors |
| DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| WO2005032399A2 (en) | 2003-05-30 | 2005-04-14 | The Regents Of The University Of California | Il4 receptor antagonists for horse, dog and cat |
| PL3718564T3 (pl) | 2003-12-23 | 2024-03-18 | Genentech, Inc. | Nowe przeciwciała anty-IL 13 i ich zastosowania |
| CN1922204A (zh) | 2004-02-27 | 2007-02-28 | 瑞泽恩制药公司 | Il－4/il－13特异性的多肽和其治疗应用 |
| EP1723173B1 (en) | 2004-02-27 | 2008-05-14 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 specific polypeptides and therapeutic uses thereof |
| US8354109B2 (en) | 2005-12-13 | 2013-01-15 | Suppremol Gmbh | Multimeric Fc receptor polypeptides |
| EP2674440B1 (en) * | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| BRPI0720280A2 (pt) * | 2006-12-11 | 2014-01-28 | Wyeth Corp | Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13 |
| US20090156421A1 (en) * | 2007-11-06 | 2009-06-18 | Wyeth | Assays and methods for evaluating multimeric complexes |
| CA2705542A1 (en) | 2007-11-13 | 2009-05-22 | Sapphire Energy, Inc. | Production of fc-fusion polypeptides in eukaryotic algae |
| EA201391607A1 (ru) | 2011-04-29 | 2014-04-30 | Янссен Байотек, Инк. | Связывающие il4/il13 белки с повторами и их применение |
| EP3842058B1 (en) | 2011-12-13 | 2023-08-23 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| EP2850093B1 (en) | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| US9574004B2 (en) | 2012-08-21 | 2017-02-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| CA2980087A1 (en) | 2015-04-02 | 2016-10-06 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| EP3328362A4 (en) * | 2015-07-29 | 2019-03-06 | Nanotics, LLC | MODULAR COMPOSITIONS FOR THE DISPOSAL OF SOLUBLE BIOMOLECULES AND RELATED METHODS |
| BR112019005964A2 (pt) | 2016-09-27 | 2019-06-18 | Epicentrx, Inc. | proteínas de fusão imunomoduladoras |
| JP7657548B2 (ja) | 2017-04-21 | 2025-04-07 | エランコ・ユーエス・インコーポレイテッド | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
| EP3870601A4 (en) | 2018-10-25 | 2022-07-13 | Kindred Biosciences, Inc. | IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE |
| EP4139344A4 (en) | 2020-04-22 | 2024-10-16 | Elanco US Inc. | Il4/il13 receptor molecules for veterinary use |
-
2018
- 2018-04-20 JP JP2019556941A patent/JP7657548B2/ja active Active
- 2018-04-20 KR KR1020257012785A patent/KR20250057131A/ko active Pending
- 2018-04-20 CA CA3059731A patent/CA3059731A1/en active Pending
- 2018-04-20 BR BR112019021812-2A patent/BR112019021812A2/pt unknown
- 2018-04-20 NZ NZ757956A patent/NZ757956A/en unknown
- 2018-04-20 WO PCT/US2018/028507 patent/WO2018195388A1/en not_active Ceased
- 2018-04-20 EP EP18788175.0A patent/EP3612555A4/en active Pending
- 2018-04-20 AU AU2018254542A patent/AU2018254542B2/en active Active
- 2018-04-20 MX MX2019012570A patent/MX2019012570A/es unknown
- 2018-04-20 KR KR1020197032241A patent/KR20200006528A/ko not_active Ceased
- 2018-04-20 CN CN201880041160.7A patent/CN110770250B/zh active Active
- 2018-04-20 US US16/605,356 patent/US11970526B2/en active Active
-
2023
- 2023-02-27 JP JP2023028068A patent/JP7776461B2/ja active Active
- 2023-03-20 AU AU2023201726A patent/AU2023201726B2/en active Active
-
2024
- 2024-03-27 US US18/617,972 patent/US20240270820A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023201726B2 (en) | 2024-11-21 |
| MX2019012570A (es) | 2019-12-02 |
| BR112019021812A2 (pt) | 2020-05-26 |
| CN110770250B (zh) | 2025-01-07 |
| US11970526B2 (en) | 2024-04-30 |
| EP3612555A4 (en) | 2020-12-30 |
| RU2019137211A3 (https=) | 2021-09-09 |
| EP3612555A1 (en) | 2020-02-26 |
| US20240270820A1 (en) | 2024-08-15 |
| WO2018195388A1 (en) | 2018-10-25 |
| JP7776461B2 (ja) | 2025-11-26 |
| US20200048325A1 (en) | 2020-02-13 |
| KR20250057131A (ko) | 2025-04-28 |
| JP2023078158A (ja) | 2023-06-06 |
| AU2018254542A1 (en) | 2019-11-21 |
| JP7657548B2 (ja) | 2025-04-07 |
| CA3059731A1 (en) | 2018-10-25 |
| AU2023201726A1 (en) | 2023-04-27 |
| AU2018254542B2 (en) | 2022-12-22 |
| KR20200006528A (ko) | 2020-01-20 |
| CN110770250A (zh) | 2020-02-07 |
| JP2020517262A (ja) | 2020-06-18 |
| RU2019137211A (ru) | 2021-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ757956A (en) | Il4/il13 receptor molecule for veterinary use | |
| MX2024012304A (es) | Anticuerpos anti-il31 para uso veterinario | |
| MX2020006668A (es) | Anticuerpos para lilrb2. | |
| MX2021004313A (es) | Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario. | |
| MX2022013149A (es) | Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario. | |
| MX2021011335A (es) | Antagonistas de ngf para uso medicinal. | |
| MX2021002971A (es) | Anticuerpos del receptor anti-interleucina 4 para uso veterinario. | |
| IL269826A (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
| JOP20200016B1 (ar) | أجسام مضادة لـ cd137 | |
| SA519401522B1 (ar) | Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات | |
| ZA201801083B (en) | Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof | |
| MY199019A (en) | Pd-1 antibodies | |
| PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
| EA201890866A1 (ru) | Связывающие молекулы, которые ингибируют рост рака | |
| MX2018003689A (es) | Proteinas de union a pd-1 y metodos para usarlas. | |
| MX2019002867A (es) | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. | |
| MX386342B (es) | Móleculas de unión a her2 y cd3 biespecíficas. | |
| BR112017020054A2 (pt) | anticorpos para icos | |
| JOP20200343A1 (ar) | بروتين ربط مولد ضد مضاد لـ steap1 | |
| MX2018006477A (es) | Anticuerpos y metodos de uso de estos. | |
| MY181106A (en) | Anti-lag3 antibodies and uses thereof | |
| PH12017502013B1 (en) | Anti-ox40 antibodies and methods of use thereof | |
| BR112016024515A2 (pt) | proteínas do agonista do receptor trail de cadeia única | |
| BR112015031719A2 (pt) | método para preparar aditivo de ração | |
| MX369696B (es) | Método y composición para mejorar la salud animal. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ELANCO US INC., US Effective date: 20231220 |